Tofadac 5
Turning the Tide on RA
Composition: Tofacitinib 5 mg
Indications
- Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Ulcerative Colitis
Tofacitinib
Drug class: Janus kinase (JAK) inhibitors
- Useful option for the treatment of adult patients with moderate to severe RA
- Is efficacious and has a manageable safety profile in patients who are negatively responding to DMARDs, DMARD MTX, or TNF inhibitors.
- Its monotherapy inhibited the progression of structural damage in methotrexate-naïve patients during ≤ 24 months’ treatment.
- Its tolerability profile was generally similar to that of biological DMARDs
